'Timing couldn't be better': An ex-generics maker goes SPAC route with blank check intended for sports market

Kyle LaHucik

Senior Reporter

Dave Mehalick originally planned for his company to be a generics maker with five drugs in the hopper. But quickly after founding Coeptis Therapeutics in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

'Timing couldn't be better': An ex-generics maker goes SPAC route with blank check intended for sports market

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

'Tim­ing could­n't be bet­ter': An ex-gener­ics mak­er goes SPAC route with blank check in­tend­ed for sports mar­ket

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

'Timing couldn't be better': An ex-generics maker goes SPAC route with blank check intended for sports market